Filing Flows

Filing Flows › CorMedix (CRMD) › Next earnings date

CorMedix (CRMD) earnings on Nov 12, 2026: what to expect

CorMedix (CRMD) is expected to report earnings on Nov 12, 2026, in 4 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.11 (−$0.20 to −$0.05, 6 estimates) on revenue of $52.8M, against $1.26 and $104M a year ago. It beat the EPS estimate in 75% of the quarters on record; Filing Flows' model gives it a 75% chance of beating next time.

Report dateNov 12, 2026
Days to go4
EPS estimate−$0.11
Revenue estimate$52.8M
Beat rate75%

What to watch

Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:

CorMedix: revenue lines, growth year over year, Q2 2026CorMedix: revenue lines, growth year over year, Q2 2026Revenue+157%Product sales, net+137%DefenCath+66%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS $2.10 on revenue of $267M, against the analysts' −$0.11.

The last report

CorMedix reported revenue of $102M for the second quarter 2026 (+156% Y/Y), net earnings $26.0M: Product sales, net $94.3M, Contract revenue $5.0M, Grant income $2.6M. How it makes money → · Every quarter →

CorMedix: EPS against the estimate, last 4 reportsCorMedix: EPS against the estimate, last 4 reportsEstimateReported$0.63$1.41Nov 25$0.81$0.16Mar 26$0.33$0.35May 26$0.24$0.29Aug 26
Latest (Aug 26): Estimate $0.24, Reported $0.29.

CorMedix's latest quarter

CorMedix, Q2 2026: revenue $102M (+156% year over year), operating margin 42.1%, net earnings $26.0M, operating cash flow $86.2M. The chart follows the revenue to costs, profit and cash.

Questions

When does CRMD report earnings?

CorMedix is expected to report on Nov 12, 2026.

What are analysts expecting from CorMedix?

EPS of −$0.11 and revenue of $52.8M for the quarter.

Does CorMedix usually beat earnings?

It beat the consensus EPS estimate in 75% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.